Get the Stockscreener App
0.3923
5.70%
-0.0237
After Hours:
.39
-0.0023
-0.59%
Jaguar Health Inc stock is traded at $0.3923, with a volume of 209.23K.
It is down -5.70% in the last 24 hours and down -49.45% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$0.416
Open:
$0.406
24h Volume:
209.23K
Relative Volume:
0.05
Market Cap:
$4.40M
Revenue:
$11.79M
Net Income/Loss:
$-41.04M
P/E Ratio:
-0.0115
EPS:
-33.9843
Net Cash Flow:
$-26.29M
1W Performance:
-6.15%
1M Performance:
-49.45%
6M Performance:
-79.93%
1Y Performance:
-91.59%
1-Day Range:
$0.383
$0.4158
1-Week Range:
$0.3805
$0.4264
52-Week Range:
$0.3805
$14.07
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.3923 | 4.67M | 11.79M | -41.04M | -26.29M | -33.98 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Entry Recap: Is Jaguar Health Inc undervalued by DCF analysisAnalyst Upgrade & Low Risk High Reward Ideas - baoquankhu1.vn
Jaguar Health Inc stock faces extreme dilution risk as proxy seeks massive share increase and dual r - AD HOC NEWS
Jaguar Health (NASDAQ: JAGX) eyes major reverse splits and note-for-equity issuance - Stock Titan
JAGX Stock Price, Quote & Chart | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
If You Invested $1,000 in Jaguar Health Inc (JAGX) - Stock Titan
Will Jaguar Health Inc outperform the market in YEAR2026 Risk Factors & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Should value investors consider Jaguar Health Inc2026 Dividend Review & AI Based Trade Execution Alerts - baoquankhu1.vn
Published on: 2026-03-20 16:46:21 - baoquankhu1.vn
JAGX Forecast, Price Target & Analyst Ratings | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) - Bitget
Jaguar Health (JAGX) Advances Pediatric Crofelemer Study - GuruFocus
FDA backs longer crofelemer trial for lethal ultra-rare childhood MVID - Stock Titan
Published on: 2026-03-19 06:11:46 - baoquankhu1.vn
Earnings Recap: Is Jaguar Health Inc stock a top performer YTDDay Trade & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Seacoastonline.com
Jaguar Health unit begins coca extract study for weight management By Investing.com - Investing.com South Africa
Jaguar Health (JAGX) Launches Preclinical Study on Coca Leaf Ext - GuruFocus
Jaguar Health unit begins coca extract study for weight management - Investing.com
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression - ACCESS Newswire
Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression - FinanzNachrichten.de
Can coca leaves help keep weight off after GLP-1 drugs end? - Stock Titan
Jaguar Health, Inc. Trade Ideas — GETTEX:1JA0 - TradingView
Performance Recap: Will Jaguar Health Inc benefit from AI trends2026 Rallies & Real-Time Buy Zone Alerts - baoquankhu1.vn
Jaguar Health (NASDAQ: JAGX) asks shareholders to OK reverse splits, large potential dilution - Stock Titan
JAGX Stock Chart | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Health at Life Sciences Forum: Strategic Shift to Rare Diseases - Investing.com
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Sheboygan Press
Director John Micek granted stock options and RSUs at Jaguar Health (JAGX) - Stock Titan
JAGX: Non-dilutive funding accelerates rare disease pipeline with strong clinical and regulatory momentum - TradingView
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts - Bradenton Herald
User - The Chronicle-Journal
Published on: 2026-03-11 18:03:23 - baoquankhu1.vn
Jaguar Health CEO to outline 'near-term catalysts' at virtual investor forum - Stock Titan
Jaguar Health, Inc. Enters Global Amendment Agreements and Security Agreement – March 2026 8-K Filing Details - Minichart
Jaguar Health (JAGX) Restructures Debt and Reduces Royalties - GuruFocus
According to the latest SEC filing, Jaguar Health Inc (NASDAQ: JAGX) has completed the amendment to the Uptown 2020 royalty interest agreement. - Bitget
Jaguar Animal Health Restructures Debt and Royalty Agreements - TipRanks
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants - ACCESS Newswire
Jaguar Health Extends Debt, Defers Royalty Payments; Terminates 48,211-Share Warrants - TradingView
Debt extensions and warrant termination reshape Jaguar Health (NASDAQ: JAGX) - Stock Titan
Jaguar Health trims $3M in debt and royalties, extends loans to July 2026 - Stock Titan
Jaguar Health executes strategic stock exchange agreements - MSN
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 - ACCESS Newswire
JAGXJaguar Health Announces a Special One-time Stock Dividend - mx.advfn.com
Jaguar Health receives Nasdaq delisting notice after share price falls below $1 - Investing.com
Revenue Check: Is Jaguar Health Inc gaining market shareJuly 2025 Weekly Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Jaguar Health Faces Nasdaq Delisting, Plans to Appeal - TipRanks
Jaguar Health Received Notice of Delisting - TradingView
Jaguar Health (NASDAQ: JAGX) confronts Nasdaq delisting risk after bid-price breach - Stock Titan
Jaguar Animal Health Declares Special Series O Dividend - The Globe and Mail
Jaguar Health receives $3M from Future Pak licensing deal By Investing.com - Investing.com India
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):